Suchergebnisse - "Remission Induction"

PubPharm (354)

51

Molekulare Prädiktoren des Tumoransprechens auf neoadjuvante Radiochemotherapie des Rektumkarzinoms

enthalten in: Der Onkologe | 2021

von Fleischmann, M. | Diefenhardt, M. | Fokas, E. | +2

52

Molekulare Prädiktoren des Tumoransprechens auf neoadjuvante Radiochemotherapie des Rektumkarzinoms

enthalten in: Der Onkologe | 2021

von Fleischmann, M. | Diefenhardt, M. | Fokas, E. | +2

53

Study for assessing the effect of blood level guided adjustment of posconazole doses (an oral drug to prevent fungal infections) in preventing fungal infections in blood cancer patients : Single arm, single centre prospective study to assess the effect of therapeutic drug monitoring (TDM) based dosage adjustment of posaconazole on the incidence of invasive fungal infections (IFIs) in AML patients on induction chemotherapy on posaconazole prophylaxis

enthalten in: WHO International Clinical Trials Registry Platform | 2021

54

Study for assessing the effect of blood level guided adjustment of posconazole doses (an oral drug to prevent fungal infections) in preventing fungal infections in blood cancer patients : Single arm, single centre prospective study to assess the effect of therapeutic drug monitoring (TDM) based dosage adjustment of posaconazole on the incidence of invasive fungal infections (IFIs) in AML patients on induction chemotherapy on posaconazole prophylaxis

enthalten in: WHO International Clinical Trials Registry Platform | 2021

55

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

56

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

57

Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis

enthalten in: Rheumatology international | 2021

von Misra, D. | Rathore, U. | Patro, P. | +2

58

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

59

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

60

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021